

STUDY PROTOCOL

Open Access



Electroacupuncture for the management of symptom clusters in cancer patients and survivors (EAST)

Lifang Xie¹, Ding Quan Ng², Matthew Heshmatipour², Munjal Acharya³, Paul Coluzzi^{3,4}, Nerida Guerrero⁵, Sanghoon Lee^{3,6}, Shaista Malik^{1,3}, Ritesh Parajuli^{3,7}, Craig Stark⁸, Rongwen Tain⁸, Keri Zabokrtsky⁵, Lilibeth Torno⁵ and Alexandre Chan^{2*}

Abstract

Background Neuropsychiatric symptoms, comprising cognitive impairment, fatigue, insomnia, depression, and anxiety, are prevalent and may co-occur during and after chemotherapy treatment for cancer. Electroacupuncture (EA), which involves mild electrical stimulation with acupuncture, holds great potential in addressing the management of individual symptoms. However, there is a lack of studies evaluating if EA can manage concurrent neuropsychiatric symptoms in cancer (i.e., symptom cluster). Hence, we designed a trial to evaluate the efficacy, safety, and feasibility of administering EA as an intervention to mitigate neuropsychiatric symptom clusters amongst cancer patients and survivors.

Methods The EAST study is a randomized, sham-controlled, patient- and assessor-blinded clinical trial. Sixty-four cancer patients and survivors with complaints of one or more neuropsychiatric symptom(s) in the seven days prior to enrollment are recruited from the University of California Irvine (UCI) and Children's Hospital of Orange County (CHOC). Individuals with needle phobia, metastases, bleeding disorders, electronic implants, epilepsy, exposure to acupuncture in the three months prior to enrollment, and who are breastfeeding, pregnant, or planning to get pregnant during the duration of the study will be excluded. Screening for metal fragments and claustrophobia are performed prior to the optional neuroimaging procedures. Recruited patients will be randomized (1:1) in random blocks of four or six to receive either ten weekly verum EA (treatment arm, vEA) or weekly sham EA (control arm, sEA) treatment visits with a follow-up appointment four to twelve weeks after their last treatment visit. The treatment arm will receive EA at 13 acupuncture points (acupoints) chosen for their therapeutic effects, while the control arm receives minimal EA at 7 non-disease-related acupoints. Questionnaires and cognitive assessments are administered, and blood drawn to assess changes in symptom clusters and biomarkers, respectively.

Conclusion The EAST study can provide insight into the efficacy of EA, an integrative medicine modality, in the management of cancer symptom clusters in routine clinical practice.

Trial registration This trial is registered with *clinicaltrials.gov* NCT05283577.

*Correspondence:
Alexandre Chan
a.chan@uci.edu

Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Keywords Electroacupuncture, Cancer, Symptom cluster, Integrative oncology, Randomized controlled trial

Background

As of January 2019, it was estimated that there were 16.9 million cancer survivors in the United States, and this number was projected to increase by 31.4%, to 22.2 million by 2030 and to 26.1 million by 2040 [1]. Many cancer survivors often experience a range of physical symptoms and neuropsychiatric burdens throughout and after their chemotherapy treatment, including fatigue, pain, insomnia, anxiety, alteration in cognitive function, and depression, reducing both quality of life and functionality [2]. It is estimated that up to 70% of cancer survivors experience six or more co-occurring symptoms [3]. Although pharmacologic and psychological treatments are used to treat specific symptoms, management of symptom clusters, defined as co-occurring related symptoms, remains challenging because none of these current pharmacological and psychological treatments are designed to address a broad range of symptoms that patients are experiencing concurrently [4]. Nonpharmacologic, complementary, and alternative medicine therapies, such as acupuncture, hold promise as a clinical treatment for the reduction of multiple co-occurring symptoms among cancer survivors.

Acupuncture is an integrative medicine technique involving the insertion of single-use, sterile fine needles into specific acupuncture points (acupoints) on the body linked to unwanted symptoms [5]. Acupuncture, which originated in Eastern Asia, has been employed widely to treat numerous disease conditions for over 2,500 years; its benefits have been recognized gradually by Western society [6]. Electroacupuncture (EA) was developed around the mid-1900s and is a modified form of acupuncture with a mild electric current passing between pairs of acupuncture needles. Although it is still not widely utilized, EA has been shown to achieve similar, or even better effects, compared to classical manual acupuncture [7]. Whereas the efficacy of acupuncture depends mainly on the manipulation technique of the individual acupuncturist, EA can be more reproducible by setting objective and quantifiable frequencies and intensities, thus making it more suitable for both basic and clinical research [7]. Recently, a study on integrative oncology service showed that acupuncture is one of the most frequently applied integrative oncology services in the United States and the European Union [8]. Evidence supports acupuncture as an effective clinical treatment for reducing individual symptoms of cancer-related fatigue [9–18], insomnia, [19–21] depression and anxiety [12, 14, 15, 22, 23], and cognitive impairment [24, 25]. This would be the first randomized controlled trial assessing the effects of acupuncture across symptom clusters in cancer survivors.

In this study, we aim to compare the efficacy of verum EA (vEA) treatment versus sham EA (sEA) in reducing cognitive toxicity, fatigue, psychological distress, insomnia, and to improve quality of life; to evaluate the impact of vEA versus sEA on biomarkers, including circulating brain-derived neurotrophic factor (BDNF), pro-inflammatory cytokines (IL-1 β , IL-4, IL-6, IL-8, IL-10, TNF- α), mitochondrial DNA (oxidative stress indicator); to determine, in a sub-set of participants, the impact of vEA vs. sEA treatments on brain structure and function; and to assess the safety and feasibility of administering vEA to manage symptom clusters in cancer patients and cancer survivors for a future multicentered, pragmatic clinical trial.

Methods

Study design

This study is a randomized, sham-controlled, patient and assessor-blinded trial. The study protocol was approved by the institutional review board at the University of California, Irvine (UCI) and via reliance agreement with Children's Hospital of Orange County (CHOC) and their institution's respective institution review board (IRB). The protocol has been registered at ClinicalTrials.gov (NCT05283577). A total of 64 patients will be randomly assigned to a vEA or a sEA group in a 1:1 ratio. Forty of the 64 recruited participants will be recruited for the optional neuroimaging sub-study.

Study locations

The administration of EA will occur at the Susan Samueli Integrative Health Clinic at the UCI main campus. The MRI for the optional neuroimaging sub-study will be done at the FIBRE imaging center, located at the UCI main campus, where we will also consent patients for our study, when applicable. The study will be utilizing the services of the Center for Clinical Research (CCR) at the UCI main campus for blood draws and administering the study questionnaires and the Cambridge Neuropsychological Test Automated Battery (CANTAB®) tests. Consenting of participants to the study will also occur at the CCR, when applicable.

Participants

Participants will be recruited from the UCI Medical Centers by advertisements, practitioner referrals, and the UC Health Data Warehouse's Honest Brokers System. We will also utilize the Consent-2-Contact Registry from the UCI Institute for Memory Impairments and Neurological Disorders (UCI MIND) for patients who previously expressed interest in clinical trials and who fit the

eligibility criteria of the study [26]. Adolescent and young adult patients will be recruited from the Hyundai Cancer Institute at CHOC.

The study will be fully explained by a member of the study team and written informed consent will be obtained by a study investigator from each participant before entering the trial.

Inclusion criteria

1. Diagnosed with cancer and have received anti-cancer treatment.
2. ≥ 16 years of age.
3. Life expectancy ≥ 6 months.
4. Complaints of two or more of the following symptoms: Memory impairment/attention deficit, fatigue, insomnia, depression, or anxiety over the past seven days.
5. Able to provide informed consent to participate in the study.

Exclusion criteria

1. Cancer that has spread to one or more organs.
2. Severe needle phobia.
3. Severe psychiatric or medical disorders that would affect cognitive assessments.
4. Known bleeding disorder (e.g., hemophilia, Von Willebrand's disease, thrombocytopenia).
5. Pacemaker or other electronic metal implants.
6. Epilepsy.
7. Received acupuncture therapy within the past three months prior to study enrolment.
8. Pregnant, breastfeeding, or are planning to get pregnant during the study period.

Exclusion requirements for optional functional MRI scan

1. Severe claustrophobia.
2. Non-removable metal orthodontic braces, metallic retainers, and oral wires.
3. Metal fragments in the body.

Randomization, allocation, and blinding

After signing the informed consent, a total of 64 eligible participants will be stratified by recruitment sites [UCI ($n=34$) or CHOC ($n=30$)] and randomized in random blocks of four or six to receive either weekly vEA or weekly sEA. The practitioner who will perform the acupuncture treatment will then provide that intervention to the participant. The participants, outcome assessors, and statisticians will be blinded to the treatment allocation. Acupuncturist blinding cannot be achieved due to the nature of the intervention.

Study procedures and time points

Once a week for 10–12 weeks, participants will receive their respective treatments. The two-week buffer will be considered in the event of unexpected, missed treatment visits, such as illness or COVID-19 exposure. During the treatment period, there will be three time points at which participants will complete five questionnaires, a computerized neuropsychological test and have their blood collected for biomarker assessment. For the five questionnaires, study participants will be given the option to have the questionnaires administered before their treatment visit remotely. There will be a follow-up visit four to twelve weeks after their last EA treatment, where participants will again be assessed using the same questionnaires and cognitive tests and having their blood drawn for biomarker assessment. In terms of the optional neuroimaging aspect of our study, participants opting in will undergo an fMRI at baseline before they begin the treatments and after they finish their tenth and final treatment. In summary, the time points are as follows (Fig. 1):

- Time point 1 (T1): Before initiation of verum EA or sham EA treatment.
- Time point 2 (T2): Between the 4th and 5th treatment visits.
- Time point 3 (T3): Within 1 week after the last planned verum EA or sham EA treatment visit.
- Time point 4 (T4): At least 4 weeks and up to 12 weeks after the last planned verum EA or sham EA treatment visit.

Study instruments

- AcuBEST brand disposable, sterilized stainless-steel acupuncture needles (size 0.20×25 mm) with FDA 510k approval for administering acupuncture treatment.
- Study data will be collected and managed using REDCap electronic data capture tools hosted at UCI [27, 28]. REDCap (Research Electronic Data Capture) is a secure, web-based software platform designed to support data capture for research studies, providing (1) an intuitive interface for validated data capture; (2) audit trails for tracking data manipulation and export procedures; (3) automated export procedures for seamless data downloads to common statistical packages; and (4) procedures for data integration and interoperability with external sources.
- OnCore™ clinical trial management system for storing patient information and assigning patient identifiers.
- EPIC Hyperspace at UCI and Cerner PowerChart at CHOC for accessing patient histories and other relevant information.
- CANTAB® for assessing objective cognitive function.
- 3T Siemens Prisma scanner for fMRI neuroimaging.




Fig. 1 Study flow chart. Time point 1 (T1): Before initiation of verum EA or sham EA treatment; Time point 2 (T2): Between the 4th and 5th treatment visits; Time point 3 (T3): Within 1 week after the last planned verum EA or sham EA treatment visit; Time point 4 (T4): At least 4 weeks, and up to 12 weeks, after the last planned verum EA or sham EA treatment visit

- ELISA kits for measuring the concentration of biomolecules (e.g., IL-6) in the blood.
- Quantitative PCR (qPCR) machine for measuring mitochondrial DNA levels.

Interventions

Verum EA group

Participants in the vEA group will receive acupuncture at disease-related acupoints: Shenting (GV24), Baihui (GV20), Sishencong (EX-HN1), Zhongwan (CV12), Guanyuan (CV4), Neiguan (PC6) bilateral, Shenmen (HT7) bilateral, Zusanli (ST36) bilateral, Sanyinjiao (SP6) bilateral, Taixi (KI3) bilateral, Zhaohai (KI6) bilateral, Hegu (LI4) bilateral, and Taichong (LR3) bilateral. With a supine position, needles will be subgaleally inserted at an angle of 15–30° along the scalp at GV24, EX-HN1, and GV20, while other body points listed above will be punctured perpendicularly. The depth of insertion will be 9–24 mm, depending on the location of the needle [29, 30]. Electrodes from the EA apparatus will be attached to each needle handle following needle insertion, and the EA stimulation will last for 30 min with a continuous wave of 2 Hz. The Baihui (GV20) and Shenting (GV24) needles are connected with electrodes. The four Sishencong (EX-HN1) electrodes are connected in pairs with one another. The Hegu (LI4) -Taichong (LR3), Neiguan (PC6)-Shenmen (HT7), Zusanli (ST36)-Sanyinjiao (SP6), and Taixi (KI3)-Zhaohai (KI6) pairs connected bilaterally. Finally Zhongwan (CV12) and Guanyuan (CV4) points are connected with one another. The EA intensity will be adjusted to be neither too strong nor uncomfortable

depending on the individual's threshold and sensitivity. Participants will receive one treatment session per week for 10 consecutive weeks for a total of 10 sessions. Locations of the acupoints are summarized in Table 1 [30, 31].

Sham EA group

Participants in the sEA group will receive acupuncture at non-disease related acupoints: Pianli (LI6) bilateral, Wenshi (LI7) bilateral, Fuyang (BL59) bilateral, Kunlun (BL60) bilateral, Sanyangluo (TE8) bilateral, Sidu (TE9) bilateral, and Daheng (SP15) bilateral with a superficial insertion and 2 Hz stimulation on each acupoint continuously for 30 min. The sEA provides minimal electrical stimulation with no distinguishable difference in sound as vEA.

Throughout the trial, all the participants will be treated separately to prevent communication. Furthermore, to ensure proper reporting of our acupuncture-based study, we referenced the STRICTA 2010 checklist shown in Table 2 [32].

Sample size calculation

Based on our previous psychometric study of the Functional Assessment of Cancer Therapy – Cognitive Function (FACT-Cog) questionnaire, a decrease of 6.9–10.6 points (4.7–7.2% of the total score) in the FACT-Cog corresponds to the threshold for clinically significant cognitive deterioration in breast cancer patients [33]. In our previous prospective cohort study, among 131 participants who completed the study, their mean and standard deviation (SD) of FACT-Cog total score prior to chemotherapy initiation, six weeks following chemotherapy

Table 1 Summary of the acupoint locations

Verum EA Acupoints	Location
Shenting (GV24)	On the head, 0.5 B-cun ^a superior to the anterior hairline, on the anterior median line. When the anterior hairline is unclear or changed, GV 24 is located 3.5 B-cun superior to the midpoint between the medial ends of the eyebrows.
Baihui (GV20)	On the head, 5 B-cun superior to the anterior hairline on the anterior median line.
Sishencong (EX-HN1)	A group of four points at the vertex, 1 B-cun from GV20 in a cross-formation
Zhongwan (CV12)	On the upper abdomen, 4 B-cun superior to the center of the umbilicus, on the anterior median line.
Guanyuan (CV4)	On the lower abdomen, 3 B-cun inferior to the center of the umbilicus, on the anterior median line.
Neiguan (PC6)	On the anterior aspect of the forearm, between the tendons of the palmaris longus and the flexor carpi radialis, 2 B-cun proximal to the palmar wrist crease
Shenmen (HT7)	On the anteromedial aspect of the wrist, radial to the flexor carpi ulnaris tendon, on the palmar wrist crease.
Hegu (LI4)	On the dorsum of the hand, radial to the midpoint of the second metacarpal bone
Zusanli (ST36)	On the anterior aspect of the leg, about one finger-breadth lateral to the tibia, 3 B-cun inferior to ST35 (On the anterior aspect of the knee, in the depression lateral to the patellar ligament).
Sanyinjiao (SP6)	On the tibial aspect of the leg, posterior to the medial border of the tibia, 3 B-cun superior to the prominence of the medial malleolus.
Taixi (KI3)	On the posteromedial aspect of the ankle, in the depression between the prominence of the medial malleolus and the calcaneal tendon.
Zhaohai (KI6)	On the medial aspect of the foot, 1 B-cun inferior to the prominence of the medial malleolus, in the depression inferior to the medial malleolus.
Taichong (LR3)	On the dorsum of the foot, between the first and second metatarsal bones, in the depression distal to the junction of the bases of the two bones, over the dorsalis pedis artery.

^aThis method uses landmarks on the body surface, such as joints, divides the length between two points into equal portions and locates acupuncture points by such proportions. Each portion equals 1 B-cun.

Table 2 STRICTA 2010 checklist

Item	Detail
1. Acupuncture rationale	1a) Style of acupuncture - Traditional Chinese Medicine 1b) Reasoning for treatment provided, based on historical context, literature sources, and/or consensus methods, with references where appropriate - Expert group consensus based on historical context 1c) Extent to which treatment was varied - No variation
2. Details of needling	2a) Number of needle insertions per subject per session (mean and range where relevant) - vEA (13 acupoints, total 24 needles including bilateral ones) vs. sEA (7 acupoints, total 14 needles including bilateral ones) 2b) Names (or location if no standard name) of points used (uni/bilateral) - See Table 1. 2c) Depth of insertion, based on a specified unit of measurement, or on a particular tissue level vEA 9–24 mm, 15–30° at GV24, EX-HN1, and GV20, and 90° at other body points. 2 Hz individually adjusted EA intensity. sEA - a superficial insertion, 2 Hz minimal EA stimulation with the same EA sounds 2d) Response sought (e.g. <i>de qi</i> or muscle twitch response) - vEA with de qi, sEA without de qi, 2e) Needle stimulation (e.g. manual, electrical)- EA 2f) Needle retention time- 30 min 2 g) Needle type (diameter, length, and manufacturer or material) - size 0.20 × 25 mm, AcuBEST(South El Monte, USA)
3. Treatment regimen	3a) Number of treatment sessions - 10 sessions 3b) Frequency and duration of treatment sessions - 1 per week * 30 min
4. Other components of treatment	4a) Details of other interventions administered to the acupuncture group (e.g. moxibustion, cupping, herbs, exercises, lifestyle advice)- N/A 4b) Setting and context of treatment, including instructions to practitioners, and information and explanations to patients - a randomized, sham-controlled, patient and assessor-blinded trial
5. Practitioner background	5) Description of participating acupuncturists (qualification or professional affiliation, years in acupuncture practice, other relevant experience) - Two California licensed acupuncturists with PhD degrees with more than 20 years of acupuncture practice.
6. Control or comparator interventions	6a) Rationale for the control or comparator in the context of the research question, with sources that justify this choice - non-disease related acupoints 6b) Precise description of the control or comparator. If sham acupuncture or any other type of acupuncture-like control is used, provide details as for Items 1 to 3 above - Mentioned in 1 to 3

initiation (end of cycle 2), 12 weeks following chemotherapy initiation (end of cycle 4), and approximately 15-months post-chemotherapy initiation (post - chemotherapy evaluation) were estimated to be 132.00 (SD 15.65), 130.23 (19.44), 128.51 (19.93) and 127.53 (21.89), respectively [34]. Assuming the correlation between observations on the same participant across time is 0.2 and a common standard deviation of two groups is 20.5, with 29 evaluable participants per group, a total of 58 evaluable participants, a power of 80% will be achieved to detect the difference of 9.6 in means of FACT-Cog total score between two groups across four time points with a p value of 0.05. After accounting a potential 10% attrition, 64 eligible patients will be enrolled into the study. Forty of the 64 participants will be recruited for the optional fMRI neuroimaging study.

Outcomes

Primary outcome measures

Self-perceived cognitive function – All study participants will complete the FACT-Cog version 3 questionnaire to assess self-perceived subjective cognitive function.

Secondary Outcome Measures

- a. Objective cognitive function – All study participants will complete CANTAB®, to assess objective cognitive functions. CANTAB® is a computerized cognitive testing software to assess selected cognitive domains of memory (paired associates learning, PAL), response speed (reaction time, RTI), executive function (spatial working memory, SWM; multitasking test, MTT) and attention (rapid visual information processing, RVP). Both self-perceived and objective assessments are recommended by the International Cognition and Cancer Task Force (ICCTF) [35].
- b. Fatigue – Multidimensional Fatigue Symptom Inventory – Short Form (MFSI-SF) is a validated questionnaire comprises of 30 items and contains five subscales (general fatigue, physical fatigue, emotional fatigue, mental fatigue, and vigor), each with six items.
- c. Psychological distress and insomnia – The Rotterdam Symptom Checklist (RSCL) will be used to measure psychological symptoms (anxiety and depression) and insomnia. Psychological distress is indicated by a score of greater than 16 in the psychological domain. Insomnia is measured by a single item in the checklist.
- d. Quality of life
 - The European Organisation for Research and Treatment (EORTC) Quality of Life of Cancer Patients (QLQ-C30) is a validated questionnaire for assessing the health-related quality of life of cancer patients participating in international clinical trials. It incorporates five functional scales (cognitive, emotional, physical, role, and social), several symptom scales (e.g., pain, fatigue, insomnia), and a global health scale.
- e. Plasma biomarker assessment – 10 mL of peripheral blood will be collected from each study participant in purple (or lavender) top K2 EDTA tubes at four timepoints: Baseline, before initiation of treatment with vEA or sEA; between fourth and fifth treatments; within one week of completing treatment; and four to 12 weeks after completing treatment. The EDTA tube will be centrifuged at $1000 \times g$ for 10 min within 30 min of collection. Plasma will be aliquoted and stored aseptically at -80°C until analysis. Plasma BDNF and cytokines (IL-1 β , IL-4, IL-6, IL-8, IL-10, TNF-alpha) levels will be quantified using commercially available ELISA kits. Mitochondrial DNA will be quantified using quantitative PCR. Please refer to our previous studies for analytical methods [36–38].
- f. Neuroimaging – In a subset of study participants recruited from UCI, gray matter and white matter volumes, diffusional weighted imaging (DWI) measures (mean diffusivity, fractional anisotropy, radial, and axial diffusivities as well as higher-order NODDI metrics), and resting state functional connectivity of different neural networks will be assessed using MRI at 3T using a Siemens Prisma scanner.
- g. Feasibility
 - **Recruitment:** Recruitment will be evaluated as the number of participants recruited (% of target recruitment) and rate of recruitment a month. Reasons for declining the participation will also be documented. Additionally, time spent on recruitment will be examined to assess recruitment productivity.
 - **Compliance:** Compliance will be measured as the number of acupuncture sessions successfully completed, and the proportion of participants completing the scheduled acupuncture sessions.
 - **Blinding and patient acceptance:** All participants will complete a questionnaire created by the investigators evaluating their perceptions towards the EA treatment at the end of study period. Participants will be asked whether they believe that they have received vEA or sEA, if they

are satisfied and benefited from the treatment, and whether they would consider undergoing treatment again outside of a trial setting.

- h. Safety – Participants will be monitored for adverse events such as feeling faint after acupuncture treatment, minor bruising, pain or discomfort, bleeding, and possible infections. Severity will be graded, when appropriate, according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5. All adverse events will be reported immediately and recorded in the case report form (CRF).

Statistical analyses

Categorical variables (participants recruited, acupuncture sessions completed, participants completing all sessions, adverse events, participant responses to acceptability questionnaire) will be analyzed using descriptive statistics, presented as counts and percentages. All the descriptive statistics will be constructed for the entire cohort and stratified by the treatment allocation. All the mean scores of symptoms and quality of life measures gathered from the different questionnaires will be compared at T1 (baseline), T2, T3, and T4 for vEA and sEA groups. The mean score changes will also be compared between the vEA and sEA groups at T2, T3, and T4. Biomarkers (BDNF, cytokines, and mitochondrial DNA level) changes will be compared between treatment groups. Mixed effects model, with random intercepts for individual participants, will be generated to evaluate the changes of symptoms and biomarkers over time, and its association with the treatment allocation (vEA or sEA). The covariates of interest include the treatment indicator (vEA or sEA), the time variable, and the interaction term treatment \times time. Both intention-to-treat and per-protocol analyses will be conducted. A significance level of 0.05 will be used, and all statistical analyses will be performed using Stata 16.

Data collection and management

To warrant quality of the data, a well-trained assessor will be responsible for data collection and recording on the CRF on Microsoft Teams. Double entry of the data into REDCap will be implemented by clinical research coordinators. Regular monitoring of the recruitment, intervention, and assessment processes will be performed to ensure predetermined protocol and standard operating procedures are followed. All study documentation will be stored in a locked cabinet in an area with limited access. In addition, participants will be registered on the electronic health record (EHR) system, EPIC, where they will have their information secured electronically. Participant information will also be stored in OnCore, a secure clinical trial management system.

Study dissemination

In addition to disseminating our results to ClinicalTrials.gov and peer-reviewed journals, we intend to present results at relevant conventions and professional meetings.

Discussion

Patients receiving chemotherapy face a group of unpleasant physical and psychological symptoms, such as fatigue, anxiety, depression, sleep disturbance, and cognitive impairment, often co-occurring as symptom clusters. These symptom clusters can have profoundly negative effects on patients' quality of life.

Numerous studies have indicated that oriental medicine not only alleviates symptoms (e.g., fatigue, chronic pain, anorexia/cachexia, and insomnia) of patients with cancer and improves their quality of life but also diminishes adverse reactions and complications caused by chemotherapy or radiotherapy. Acupuncture, one of the major components of oriental medicine, is an available complementary therapy to relieve cancer- and treatment-related complications. More importantly, EA is readily replicable due to its standardized interventional approach [7].

This study will be the first clinical trial that assesses the effects of EA across multiple symptom clusters in cancer patients and survivors. The findings from this trial will be an encouraging step toward expanding survivorship care to meet the needs of the growing cancer survivor population. Understanding symptom clusters in cancer survivors may result in greater therapeutic benefits by integrating treatments for concurrent symptoms, thus improving quality of life [39]. In addition to quality of life, mitigation or complete resolution of multiple symptoms will also positively affect prognosis and functional status of those afflicted [40]. The hypothesis from this study, to target comorbid cognitive, affective, and somatic symptoms simultaneously, will open new avenues of exploration. This study will also uniquely leverage a translational approach to understand how objective biomarkers are linked with the change of various symptoms over treatment. Results of this trial will propel the use of evidence-based integrative health treatment modalities in managing cancer patients' well-being.

Conclusion

Overall, this study will determine the efficacy of utilizing EA as an intervention for treating symptom clusters in cancer patients and survivors. If successful, the results of our study can provide clinical significance in implementing integrative medicine as a modality in the management of symptom clusters in cancer patients and survivors.

Abbreviations

EA	Electroacupuncture
B-cun	Proportional Bone (skeletal) cun
vEA	Verum Electroacupuncture
sEA	Sham Electroacupuncture
RCT	Randomized Controlled Trial

Acknowledgements

This material is based on work supported by The Regents of the University of California.

We would like to thank the California Breast Cancer Research Program (CBCRP) 2022 - Innovative, Developmental, and Exploratory Award (IDEA) (Grant ID: B28IB5461) and the UCI CFCCC Anti-Cancer Challenge 2022 Pilot Project Award for providing funding to this study. We would also like to thank UCI MIND and the Breast Cancer Angels for providing their support to our study.

Authors' contributions

AC, LX, SM, SL and DQN conceived the study, developed the methods, and participated in the study design. DQN, MH, MA, PC, NG, RP, CS, RT, KZ and LT are involved in the data collection process. All authors contributed to the drafting the final manuscript and approved the final manuscript.

Funding

Open Access funding enabled and organized by Projekt DEAL. Funding is provided by the California Breast Cancer Research Program (CBCRP), the UCI CFCCC Anti-Cancer Challenge 2022 Pilot Project.

Data availability

The data collected and presented for our research can be found at ClinicalTrials.gov **NCT05283577**.

Declarations

Trial status

Our trial has been approved by the UCI IRB (IRB #20216732). We foresee the study will be completed in the first quarter of 2024.

Ethics approval and consent to participate

All aspects of this study abide by the ethical guidelines put in place by the Nuremberg Code, the Declaration of Helsinki, and the Belmont Report. All participants involved in this study will be made aware of the potential risks and harms of this study and will be screened to ensure they are able to give consent. They will be made aware of any potential direct benefits and reminded of the three principles underlying the ethical conduct of research: Respect for persons, Beneficence, and Justice. The study was approved by the UC Irvine Institutional Review Board on September 12, 2022 (Reviewed by Farshid Dayyani, MD, PhD UCI IRB #20216732).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Susan Samueli Integrative Health Institute, University of California Irvine Health, Irvine, CA, USA

²Department of Clinical Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University of California Irvine, Irvine, CA, USA

³School of Medicine, University of California Irvine, Irvine, CA, USA

⁴Pacific Breast Cancer Center, University of California Irvine Health, Irvine, CA, USA

⁵Department of Pediatric Hematology/Oncology, Hyundai Cancer Institute at Children's Healthcare of Orange County, Orange, CA, USA

⁶College of Korean Medicine, Kyung Hee University, Seoul, South Korea

⁷UCI Chao Family Comprehensive Cancer Center, Orange, CA, USA

⁸The Facility for Imaging and Brain Research (FIBRE), University of California Irvine, Irvine, CA, USA

References

1. American Cancer Society. Cancer Treatment & survivorship facts & Figs. 2019–2021. Atlanta: American Cancer Society; 2019.
2. Lengacher CA, Reich RR, Post-White J, Moscoso M, Shelton MM, Barta M, et al. Mindfulness based stress reduction in post-treatment breast cancer patients: an examination of symptoms and symptom clusters. *J Behav Med.* 2012;35(1):86–94.
3. Fu OS, Crew KD, Jacobson JS, Greenlee H, Yu G, Campbell J, et al. Ethnicity and persistent symptom burden in breast cancer survivors. *J Cancer Surviv.* 2009;3(4):241–50.
4. Kim HJ, Barsevick AM, Fang CY, Miaskowski C. Common biological pathways underlying the psychoneurological symptom cluster in cancer patients. *Cancer Nurs.* 2012;35(6):E1–E20.
5. Kaptchuk TJ. Acupuncture: theory, efficacy, and practice. *Ann Intern Med.* 2002;136(5):374–83.
6. Murray P, Shurtleff D, Langevin H, Acupuncture. What You Need To Know [Received: 2 March 2023 / Accepted: 17 March 2023](https://www.nccih.nih.gov/health/acupuncture-what-you-need-to-know#:~:text=What%20is%20acupuncture%3F,for%20at%20least%202%2C500%20years.: NCCIH; 2022 [
7. Napadow V, Makris N, Liu J, Kettner NW, Kwong KK, Hui KK. Effects of electroacupuncture versus manual acupuncture on the human brain as measured by fMRI. <i>Hum Brain Mapp.</i> 2005;24(3):193–205.
8. Grant SJ, Hunter J, Seely D, Balneaves LG, Rossi E, Bao T. Integrative oncology: International Perspectives. <i>Integr Cancer Ther.</i> 2019;18:1534735418823266.
9. Johnston MF, Hays RD, Subramanian SK, Elashoff RM, Axe EK, Li JJ, et al. Patient education integrated with acupuncture for relief of cancer-related fatigue randomized controlled feasibility study. <i>BMC Complement Altern Med.</i> 2011;11:49.
10. Smith C, Carmady B, Thornton C, Perz J, Ussher JM. The effect of acupuncture on post-cancer fatigue and well-being for women recovering from breast cancer: a pilot randomised controlled trial. <i>Acupunct Med.</i> 2013;31(1):9–15.
11. Foroughipour M, Bahrami Taghanaki HR, Saeidi M, Khazaei M, Sasannezhad P, Shoeibi A. Amantadine and the place of acupuncture in the treatment of fatigue in patients with multiple sclerosis: an observational study. <i>Acupunct Med.</i> 2013;31(1):27–30.
12. Molassiotis A, Bardy J, Finnegan-John J, Mackereth P, Ryder DW, Filshie J, et al. Acupuncture for cancer-related fatigue in patients with breast cancer: a pragmatic randomized controlled trial. <i>J Clin Oncol.</i> 2012;30(36):4470–6.
13. Deng G, Chan Y, Sjoberg D, Vickers A, Yeung KS, Kris M, et al. Acupuncture for the treatment of post-chemotherapy chronic fatigue: a randomized, blinded, sham-controlled trial. <i>Support Care Cancer.</i> 2013;21(6):1735–41.
14. Yu M, Li D, Yang G, Xu Y, Wang X. Effects of acupuncture on cancer-related fatigue in breast cancer patients at the rehabilitation stage: a randomized controlled trial. <i>China Med Herald.</i> 2017;14(19):89–93.
15. Mao JJ, Farrar JT, Bruner D, Zee J, Bowman M, Seluzicki C, et al. Electroacupuncture for fatigue, sleep, and psychological distress in breast cancer patients with aromatase inhibitor-related arthralgia: a randomized trial. <i>Cancer.</i> 2014;120(23):3744–51.
16. Cheng CS, Chen LY, Ning ZY, Zhang CY, Chen H, Chen Z, et al. Acupuncture for cancer-related fatigue in lung cancer patients: a randomized, double blind, placebo-controlled pilot trial. <i>Support Care Cancer.</i> 2017;25(12):3807–14.
17. Lu W, Posner MR, Wayne P, Rosenthal DS, Haddad RI. Acupuncture for dysphagia after chemoradiation therapy in head and neck cancer: a case series report. <i>Integr Cancer Ther.</i> 2010;9(3):284–90.
18. Zhang Y, Lin L, Li H, Hu Y, Tian L. Effects of acupuncture on cancer-related fatigue: a meta-analysis. <i>Support Care Cancer.</i> 2018;26(2):415–25.
19. Choi TY, Kim JJ, Lim HJ, Lee MS. Acupuncture for managing Cancer-Related Insomnia: a systematic review of Randomized clinical trials. <i>Integr Cancer Ther.</i> 2017;16(2):135–46.
20. Zhang J, Zhang Z, Huang S, Qiu X, Lao L, Huang Y, et al. Acupuncture for cancer-related insomnia: a systematic review and meta-analysis. <i>Phytomedicine.</i> 2022;102:154160.
21. Garland SN, Xie SX, Li Q, Seluzicki C, Basal C, Mao JJ. Comparative effectiveness of electro-acupuncture versus gabapentin for sleep disturbances in breast cancer survivors with hot flashes: a randomized trial. <i>Menopause.</i> 2017;24(5):517–23.

</div>
<div data-bbox=)

Published online: 27 March 2023

22. Bao T, Cai L, Snyder C, Betts K, Tarpinian K, Gould J, et al. Patient-reported outcomes in women with breast cancer enrolled in a dual-center, double-blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms. *Cancer*. 2014;120(3):381–9.
23. Walker EM, Rodriguez AI, Kohn B, Ball RM, Pegg J, Pocock JR, et al. Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: a randomized controlled trial. *J Clin Oncol*. 2010;28(4):634–40.
24. Zhang Y, Zhang C, Xu X, Zhang Q. Clinical observation on acupuncture of reconciling Qi and blood, tonifying heart and mind method in the treatment of 53 patients of breast cancer chemotherapy-related cognitive impairment with disorder of Qi and blood syndrome. *J Tradit Chin Med*. 2019;60(6):13.
25. Lyu YR, Lee HY, Park HJ, Kwon OJ, Kim AR, Jung IC, et al. Electroacupuncture for Cancer-Related cognitive impairment: a clinical feasibility study. *Integr Cancer Ther*. 2022;21:15347354221098983.
26. Grill JD, Hoang D, Gillen DL, Cox CG, Gombosov A, Klein K, et al. Constructing a local potential participant Registry to improve Alzheimer's Disease Clinical Research Recruitment. *J Alzheimers Dis*. 2018;63(3):1055–63.
27. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, McLeod L, Delacqua G, Delacqua F, Kirby J, Duda SN. REDCap Consortium, The REDCap consortium: Building an international community of software partners, *J Biomed Inform*. 2019 May 9 <https://doi.org/10.1016/j.jbi.2019.103208>
28. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap) – A metadata-driven methodology and workflow process for providing translational research informatics support, *J Biomed Inform*. 2009 Apr;42(2):377 – 81
29. Kim JH, Cho MR, Park GC, Lee JS. Effects of different acupuncture treatment methods on mild cognitive impairment: a study protocol for a randomized controlled trial. *Trials*. 2019;20(1):551.
30. Lim S, WHO Standard Acupuncture Point Locations. *Evid Based Complement Alternat Med*. 2010;7(2):167–8.
31. Maciocia G. The foundations of Chinese Medicine: A Comprehensive text for Acupuncturists and Herbalists. Churchill Livingstone; 1989.
32. MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, et al. Revised Standards for reporting interventions in clinical trials of acupuncture (STRICTA): extending the CONSORT statement. *J Altern Complement Med*. 2010;16(10):T1–14.
33. Cheung YT, Foo YL, Shwe M, Tan YP, Fan G, Yong WS, et al. Minimal clinically important difference (MCID) for the functional assessment of cancer therapy: cognitive function (FACT-Cog) in breast cancer patients. *J Clin Epidemiol*. 2014;67(7):811–20.
34. Ng T, Dorajoo SR, Cheung YT, Lam YC, Yeo HL, Shwe M, et al. Distinct and heterogeneous trajectories of self-perceived cognitive impairment among asian breast cancer survivors. *Psychooncology*. 2018;27(4):1185–92.
35. Wefel JS, Vardy J, Ahles T, Schagen SB. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. *Lancet Oncol*. 2011;12(7):703–8.
36. Toh YL, Tan CJ, Yeo AHL, Shwe M, Ho HK, Gan YX, et al. Association of plasma leptin, pro-inflammatory adipokines and cancer-related fatigue in early-stage breast cancer patients: a prospective cohort study. *J Cell Mol Med*. 2019;23(6):4281–9.
37. Yap NY, Tan NYT, Tan CJ, Loh KW, Ng RCH, Ho HK, et al. Associations of plasma brain-derived neurotrophic factor (BDNF) and Val66Met polymorphism (rs6265) with long-term cancer-related cognitive impairment in survivors of breast cancer. *Breast Cancer Res Treat*. 2020;183(3):683–96.
38. Toh YL, Wong E, Chae JW, Yap NY, Yeo AHL, Shwe M, et al. Association of mitochondrial DNA content and displacement loop region sequence variations with cancer-related fatigue in breast cancer survivors receiving chemotherapy. *Mitochondrion*. 2020;54:65–71.
39. Cheung WY, Le LW, Gagliese L, Zimmermann C. Age and gender differences in symptom intensity and symptom clusters among patients with metastatic cancer. *Support Care Cancer*. 2011;19(3):417–23.
40. Fan G, Hadi S, Chow E. Symptom clusters in patients with advanced-stage cancer referred for palliative radiation therapy in an outpatient setting. *Support Cancer Ther*. 2007;4(3):157–62.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.